Jing Li1, Kyungho Kim1,2, Si-Yeon Jeong1, Joyce Chiu3,4, Bei Xiong1, Pavel A Petukhov5, Xiangrong Dai6, Xiaoyi Li6, Robert K Andrews7, Xiaoping Du1, Philip J Hogg3,4, Jaehyung Cho1. 1. Department of Pharmacology, University of Illinois College of Medicine, Chicago (J.L., K.K., S.-Y.J, B.X., X. Du, J. Cho). 2. Korean Medicine-Application Center, Korea Institute of Oriental Medicine, Daegu (K.K.). 3. The Centenary Institute, Newtown, NSW, Australia (J. Chiu, P.J.H.). 4. National Health and Medical Research Council Clinical Trials Centre, University of Sydney, NSW, Australia (J. Chiu, P.J.H.). 5. Department of Medicinal Chemistry and Pharmacognosy, University of Illinois College of Pharmacy, Chicago (P.A.P.). 6. Lee's Pharmaceutical Holdings Ltd, Shatin, Hong Kong (X. Dai, X.L.). 7. Australian Centre for Blood Diseases, Monash University, Melbourne, VIC (R.K.A.).
Abstract
BACKGROUND: Platelet-neutrophil interactions contribute to vascular occlusion and tissue damage in thromboinflammatory disease. Platelet glycoprotein Ibα (GPIbα), a key receptor for the cell-cell interaction, is believed to be constitutively active for ligand binding. Here, we established the role of platelet-derived protein disulfide isomerase (PDI) in reducing the allosteric disulfide bonds in GPIbα and enhancing the ligand-binding activity under thromboinflammatory conditions. METHODS: Bioinformatic analysis identified 2 potential allosteric disulfide bonds in GPIbα. Agglutination assays, flow cytometry, surface plasmon resonance analysis, a protein-protein docking model, proximity ligation assays, and mass spectrometry were used to demonstrate a direct interaction between PDI and GPIbα and to determine a role for PDI in regulating GPIbα function and platelet-neutrophil interactions. Also, real-time microscopy and animal disease models were used to study the pathophysiological role of PDI-GPIbα signaling under thromboinflammatory conditions. RESULTS: Deletion or inhibition of platelet PDI significantly reduced GPIbα-mediated platelet agglutination. Studies using PDI-null platelets and recombinant PDI or Anfibatide, a clinical-stage GPIbα inhibitor, revealed that the oxidoreductase activity of platelet surface-bound PDI was required for the ligand-binding function of GPIbα. PDI directly bound to the extracellular domain of GPIbα on the platelet surface and reduced the Cys4-Cys17 and Cys209-Cys248 disulfide bonds. Real-time microscopy with platelet-specific PDI conditional knockout and sickle cell disease mice demonstrated that PDI-regulated GPIbα function was essential for platelet-neutrophil interactions and vascular occlusion under thromboinflammatory conditions. Studies using a mouse model of ischemia/reperfusion-induced stroke indicated that PDI-GPIbα signaling played a crucial role in tissue damage. CONCLUSIONS: Our results demonstrate that PDI-facilitated cleavage of the allosteric disulfide bonds tightly regulates GPIbα function, promoting platelet-neutrophil interactions, vascular occlusion, and tissue damage under thromboinflammatory conditions.
BACKGROUND: Platelet-neutrophil interactions contribute to vascular occlusion and tissue damage in thromboinflammatory disease. Platelet glycoprotein Ibα (GPIbα), a key receptor for the cell-cell interaction, is believed to be constitutively active for ligand binding. Here, we established the role of platelet-derived protein disulfide isomerase (PDI) in reducing the allosteric disulfide bonds in GPIbα and enhancing the ligand-binding activity under thromboinflammatory conditions. METHODS: Bioinformatic analysis identified 2 potential allosteric disulfide bonds in GPIbα. Agglutination assays, flow cytometry, surface plasmon resonance analysis, a protein-protein docking model, proximity ligation assays, and mass spectrometry were used to demonstrate a direct interaction between PDI and GPIbα and to determine a role for PDI in regulating GPIbα function and platelet-neutrophil interactions. Also, real-time microscopy and animal disease models were used to study the pathophysiological role of PDI-GPIbα signaling under thromboinflammatory conditions. RESULTS: Deletion or inhibition of platelet PDI significantly reduced GPIbα-mediated platelet agglutination. Studies using PDI-null platelets and recombinant PDI or Anfibatide, a clinical-stage GPIbα inhibitor, revealed that the oxidoreductase activity of platelet surface-bound PDI was required for the ligand-binding function of GPIbα. PDI directly bound to the extracellular domain of GPIbα on the platelet surface and reduced the Cys4-Cys17 and Cys209-Cys248 disulfide bonds. Real-time microscopy with platelet-specific PDI conditional knockout and sickle cell diseasemice demonstrated that PDI-regulated GPIbα function was essential for platelet-neutrophil interactions and vascular occlusion under thromboinflammatory conditions. Studies using a mouse model of ischemia/reperfusion-induced stroke indicated that PDI-GPIbα signaling played a crucial role in tissue damage. CONCLUSIONS: Our results demonstrate that PDI-facilitated cleavage of the allosteric disulfide bonds tightly regulates GPIbα function, promoting platelet-neutrophil interactions, vascular occlusion, and tissue damage under thromboinflammatory conditions.
Entities:
Keywords:
blood platelets; glycoprotein Ibalpha; inflammation; neutrophils; protein disulfide isomerase
Authors: Judith Lahav; Eveline M Wijnen; Oded Hess; Samir W Hamaia; Delia Griffiths; Michael Makris; C Graham Knight; David W Essex; Richard W Farndale Journal: Blood Date: 2003-06-05 Impact factor: 22.113
Authors: Eric G Huizinga; Shizuko Tsuji; Roland A P Romijn; Marion E Schiphorst; Philip G de Groot; Jan J Sixma; Piet Gros Journal: Science Date: 2002-08-16 Impact factor: 47.728
Authors: Yunmei Wang; Huiyun Gao; Can Shi; Paul W Erhardt; Alexander Pavlovsky; Dmitry A Soloviev; Kamila Bledzka; Valentin Ustinov; Liang Zhu; Jun Qin; Adam D Munday; Jose Lopez; Edward Plow; Daniel I Simon Journal: Nat Commun Date: 2017-05-30 Impact factor: 14.919
Authors: Jing Li; Si-Yeon Jeong; Bei Xiong; Alan Tseng; Andrew B Mahon; Steven Isaacman; Victor R Gordeuk; Jaehyung Cho Journal: Haematologica Date: 2019-10-31 Impact factor: 9.941